Health


French health body probes contraceptive linked death


Lille of third-generation contraceptive pills. France's national drug agency ANSM confirmed on January 27, 2013 4 deaths linked to the Diane 35 pill, an acne treatment medicine developped by Bayert but often used as a contraceptive pill. Pic: AFP

Paris: French health regulator ANSM has launched a probe into the drug Diane-35, used to treat acne and also as a contraceptive, after linking it to four deaths over the past 25 years. Produced by the German drugmaker Bayer, Diane-35 is authorised in 135 countries and sold in 116. In 2012, about 315,000 women in France used the drug, ANSM said in a statement Sunday.

Four deaths due to thrombosis were linked to the use of Diane-35, ANSM said, promising to release a full report on the drug and its risks next week. Three other deaths reported by French newspaper Le Figaro on its website as connected to the drug were linked to existing health conditions, the regulator confirmed.

Diane-35, also sold as Dianette in some countries, is a hormone tablet that treats certain types of acne for women and is also used as a contraceptive. A database of information from French doctors shows 125 cases of thrombosis related to Diane-35 or other forms of the drug since 1987, when the drug was first released onto the market.

France announced last year that so-called third generation birth-control pills -- newer pills that contain variants of the hormone progestin -- will no longer be reimbursed by the social security system from March.

Earlier this month, ANSM launched a probe into the use of newer contraceptive pills on the market over fears of blood clots after a woman sued Bayer over an alleged clot caused by her pill.

One French lawyer told French media on Sunday that around 100 women had contacted him, intending to sue both Bayer and ANSM for not raising the alarm sooner.

Share 

 Rate this Article
Rates : 0, Average : 0

Share more.

Post a Comment

Did you like this section? Leave a comment!
Your Name : Your Email Address :
Your Comment :
Enter Image Text:
 
No Comments Posted